Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−1.14 USD
−1.64 B USD
16.51 B USD
1.15 B
About TEVA
Sector
Industry
CEO
Richard Francis
Website
Headquarters
Tel Aviv
Founded
1901
FIGI
BBG000C0CD58
Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: United States, Europe, and International Markets. The United States segment focuses on therapeutic area of central nervous system (CNS) portfolio, and is involved in the distribution business of generic, biosimilar and medicines, and over-the-counter (OTC) pharmaceutical products from the firm and third-party manufacturers to independent retail pharmacies, pharmacy retail chains, hospitals, and physician offices in the United States. The Europe segment offers OTC portfolio including SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brands in European Union, the United Kingdom, and certain other European countries. The International Markets segment provides its products to countries such as Canada, Israel, Russia, Latin America, and Japan. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.
Related stocks
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
TEVA.GJ
Teva Pharmaceutical Finance Co. LLC 0.25% 01-FEB-2026Yield to maturity
26.91%
Maturity date
Feb 1, 2026
US88167AAF84
TEVA PHARMA FIN III 4.10% CALL 01OT46Yield to maturity
7.44%
Maturity date
Oct 1, 2046
TEVA4608603
Teva Pharmaceutical Finance Netherlands III BV 6.75% 01-MAR-2028Yield to maturity
6.96%
Maturity date
Mar 1, 2028
US88163VAD10
TEVA PHARM FIN CO LLC 6.15% CALL 01FB36Yield to maturity
5.75%
Maturity date
Feb 1, 2036
CH0333827506
TEVA 1% 25Yield to maturity
5.62%
Maturity date
Jul 28, 2025
TEVA5549923
Teva Pharmaceutical Finance Netherlands III BV 7.875% 15-SEP-2029Yield to maturity
5.34%
Maturity date
Sep 15, 2029
TEVA6082388
Teva Pharmaceutical Finance Netherlands III BV 6.0% 01-DEC-2032Yield to maturity
5.33%
Maturity date
Dec 1, 2032
TEVA5549924
Teva Pharmaceutical Finance Netherlands III BV 8.125% 15-SEP-2031Yield to maturity
5.23%
Maturity date
Sep 15, 2031
TFAB
TEVA P.FI.NL III 16/26Yield to maturity
5.22%
Maturity date
Oct 1, 2026
TEVA6082389
Teva Pharmaceutical Finance Netherlands IV BV 5.75% 01-DEC-2030Yield to maturity
5.21%
Maturity date
Dec 1, 2030
TFAF
TEVA P.FI.NL III 18/28Yield to maturity
5.13%
Maturity date
Mar 1, 2028
See all TEVA bonds